Aurigene Oncology Limited announces promising results of Phase 1 study for India’s first trial for novel autologous CAR-T cell therapy for multiple myeloma

by | Oct 8, 2024 | Myeloma News | 0 comments

Source: Pharmacy Times articles

This marks India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.
Read More

Submit a Comment